Biogen, Inc. (BIIB)
164.42
-4.15
(-2.46%)
USD |
NASDAQ |
Jan 16, 16:00
167.60
+3.18
(+1.93%)
After-Hours: 20:00
Biogen EPS Diluted (Quarterly): 3.171 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 6.211 |
| AbbVie, Inc. | 0.0993 |
| Stoke Therapeutics, Inc. | -0.6543 |
| Alnylam Pharmaceuticals, Inc. | 1.840 |
| Insmed, Inc. | -1.747 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 466.50M |
| Revenue (Quarterly) | 2.455B |
| Total Expenses (Quarterly) | 1.988B |
| Enterprise Value | 26.75B |
| Gross Profit Margin (Quarterly) | 64.29% |
| Profit Margin (Quarterly) | 19.00% |
| Earnings Yield | 6.67% |
| Operating Earnings Yield | 10.12% |
| Normalized Earnings Yield | 7.522 |